Quarterly ResultMay 5, 2026, 07:08 AM
uniQure Q1 Results; AMT-130 FDA/UK Progress; $586.6M Cash
AI Summary
uniQure N.V. reported a net loss of $53.5 million on revenues of $3.6 million for the first quarter of 2026. The company is advancing its gene therapy pipeline, with a Type B meeting scheduled with the FDA for AMT-130 for Huntington's disease in Q2 2026 and a UK MAA submission on track for Q3 2026. Positive data was presented for AMT-191 in Fabry disease, leading all 11 patients to discontinue enzyme replacement therapy, though development of AMT-162 for ALS was discontinued. uniQure maintains a strong balance sheet with $586.6 million in cash, providing a runway into the second half of 2029.
Key Highlights
- Cash, cash equivalents, and current investment securities were $586.6 million as of March 31, 2026.
- Company expects cash runway into the second half of 2029.
- Net loss for Q1 2026 was $53.5 million, compared to $43.6 million in Q1 2025.
- Revenue for Q1 2026 was $3.6 million, up from $1.6 million in Q1 2025.
- R&D expenses decreased by $6.9 million to $29.2 million in Q1 2026.
- SG&A expenses increased by $9.2 million to $20.1 million in Q1 2026.
- FDA Type B meeting for AMT-130 (Huntington's disease) scheduled for Q2 2026.
- UK MAA submission for AMT-130 on track for Q3 2026.
- All 11 dosed patients in AMT-191 (Fabry disease) study discontinued enzyme replacement therapy.